Adding the immunotherapy drug pembrolizumab (Keytruda®) to chemotherapy, with or without bevacizumab (Avastin®), improved overall survival (OS) and progression-free survival (PFS) in people with persistent, recurrent, or metastatic cervical cancer, regardless of whether the cancer expressed PD-L1. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (June 2-6).
Login Or Register To Read Full Story